Literature DB >> 30190947

Current state of nonsurgical therapies for cholangiocarcinoma.

Volker Brass1, Jan B Kuhlmann1, Hubert E Blum1.   

Abstract

Cholangiocarcinomas (CCCs) are rare tumors that are derived from the epithelial cell lining of the bile ducts. They can be classified as intrahepatic, extrahepatic-perihilar and extrahepatic-distal tumors. The prognosis of CCCs is poor as, in many cases, they are diagnosed at advanced stages, at which point curative surgical resection is not possible. Furthermore, most patients will experience a tumor recurrence despite initial complete CCC resection. Therefore, alternative/additional therapeutic strategies are needed to improve tumor- and recurrence-free survival after surgery as well as tumor control in patients with advanced disease. In clinical practice, apart from systemic chemotherapies for the therapeutic management of CCCs, locoregional as well as multimodal strategies are available, including external and internal radiation therapies. This review focuses on the currently available nonsurgical therapies for patients with CCCs, alone or in combination with other modalities, and on evolving therapeutic concepts that are being explored in clinical studies.

Entities:  

Year:  2013        PMID: 30190947      PMCID: PMC6114004          DOI: 10.2217/hep.13.9

Source DB:  PubMed          Journal:  Hepat Oncol        ISSN: 2045-0923


  65 in total

1.  Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.

Authors:  Birgit Gruenberger; Johannes Schueller; Ute Heubrandtner; Fritz Wrba; Dietmar Tamandl; Klaus Kaczirek; Rudolf Roka; Sandra Freimann-Pircher; Thomas Gruenberger
Journal:  Lancet Oncol       Date:  2010-11-09       Impact factor: 41.316

2.  Phase II study of erlotinib in patients with advanced biliary cancer.

Authors:  Philip A Philip; Michelle R Mahoney; Cristine Allmer; James Thomas; Henry C Pitot; George Kim; Ross C Donehower; Tom Fitch; Joel Picus; Charles Erlichman
Journal:  J Clin Oncol       Date:  2006-07-01       Impact factor: 44.544

3.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

4.  Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study.

Authors:  Atul Sharma; Amit Dutt Dwary; Bidhu Kalyan Mohanti; Surya V Deo; Sujoy Pal; Vishnu Sreenivas; Vinod Raina; Nootan Kumar Shukla; Sanjay Thulkar; Pramod Garg; Surendra Pal Chaudhary
Journal:  J Clin Oncol       Date:  2010-09-20       Impact factor: 44.544

Review 5.  Surgical treatment in proximal bile duct cancer. A single-center experience.

Authors:  R Pichlmayr; A Weimann; J Klempnauer; K J Oldhafer; H Maschek; G Tusch; B Ringe
Journal:  Ann Surg       Date:  1996-11       Impact factor: 12.969

6.  Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report.

Authors:  Pankaj Bhargava; Chirag R Jani; Diane M Savarese; Judith L O'Donnell; Keith E Stuart; Caio M Rocha Lima
Journal:  Oncology (Williston Park)       Date:  2003-09       Impact factor: 2.990

7.  Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors.

Authors:  A Nakeeb; H A Pitt; T A Sohn; J Coleman; R A Abrams; S Piantadosi; R H Hruban; K D Lillemoe; C J Yeo; J L Cameron
Journal:  Ann Surg       Date:  1996-10       Impact factor: 12.969

8.  Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution.

Authors:  Michelle L DeOliveira; Steven C Cunningham; John L Cameron; Farin Kamangar; Jordan M Winter; Keith D Lillemoe; Michael A Choti; Charles J Yeo; Richard D Schulick
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

9.  Treatment of primary hepatobiliary cancers with conformal radiation therapy and regional chemotherapy.

Authors:  J M Robertson; T S Lawrence; L M Dworzanin; J C Andrews; S Walker; M L Kessler; D J DuRoss; W D Ensminger
Journal:  J Clin Oncol       Date:  1993-07       Impact factor: 44.544

10.  OEM-TACE: a new therapeutic approach in unresectable intrahepatic cholangiocarcinoma.

Authors:  Guido Poggi; A Amatu; B Montagna; P Quaretti; C Minoia; C Sottani; L Villani; B Tagliaferri; F Sottotetti; O Rossi; E Pozzi; F Zappoli; A Riccardi; G Bernardo
Journal:  Cardiovasc Intervent Radiol       Date:  2009-11       Impact factor: 2.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.